The Hidden Cost Baseline: Why 20–30% of Clinical Trial Spend Sits in Data Management That Nobody Optimises

Clinical trial costs have become one of the biggest constraints on pharmaceutical R&D. For Phase III trials alone, the cost of conducting a trial has been estimated at $55,716 per day, based on Tufts CSDD’s 2024 analysis of 409 protocols.
Yet when sponsors review their clinical trial budgets, data management often looks relatively contained. A typical budget may allocate around 15% of total trial cost to direct data management activities such as EDC licensing, database development, data cleaning, coding, and database lock.
That number is real, but it does not tell the whole story.
The cost of managing clinical data is spread across several parts of a trial. Monitoring, source data verification, query resolution, reconciliation between systems, and rework caused by protocol amendments may sit under different budgets and different teams.
Put those costs together, and the burden of clinical data management can be considerably larger than the line item suggests.
The 15% Budget Line Does Not Show the Full Cost
Direct data management is usually easy to identify.
It includes the systems and people responsible for building and maintaining the clinical database, cleaning data, coding medical terms, and preparing for database lock. These activities are visible, so they receive a defined place in the trial budget.
The less visible costs are more difficult to track.
For example, source data verification can consume up to 25% of clinical trial budgets, according to research cited in the source material. TransCelerate BioPharma has also reported that 46% to 50% of monitoring time can be consumed by 100% source data verification, while only 2.4% of queries on critical data fields were driven by that verification process.
There is another important piece of context: approximately 97% of electronically captured data is already accurate at entry.
That raises a practical question for sponsors: how much time and money is being spent verifying data that is already correct?
The answer is difficult to see when monitoring, data management, and clinical operations are measured separately.
Where the Hidden Cost Actually Sits
The problem is less about one expensive activity and more about how costs are distributed.
Monitoring costs may sit within clinical operations. Query resolution can consume CRA and site-management time. Reconciliation work may be handled by data managers or CRO teams. Rework caused by protocol amendments can appear within a separate operational budget.
No single budget owner necessarily sees the combined figure.
The result is a fragmented view of the cost of data quality.
Veeva’s 2025 Clinical Data Industry Research found that each data manager spends more than 12 hours per week, per study, on manual reconciliation, cleaning, and review. The reported drivers include manual steps or data re-entry, inefficient workflows, and disconnected systems.
The research also found that 97% of respondents perform data reconciliation outside clinical systems or by using a mix of systems.
That is where the hidden cost starts to become clearer.
The issue isn't simply the amount paid for an EDC platform or a data-management team. It is the accumulated labour required to make disconnected systems, processes, and data sources work together.
Protocol Amendments Add Another Layer
Protocol amendments make the problem harder to contain.
Tufts CSDD’s 2024 benchmarks indicate that 76% of Phase I to IV trials require amendments, compared with 57% in 2015. The median direct cost was reported at approximately $141,000 for Phase II and $535,000 for Phase III protocols.
An amendment does not stop with a revised document.
Changes can flow into EDC configuration, edit checks, data collection requirements, monitoring activities, and reconciliation processes. Teams may need to review or rework existing data structures and workflows.
Those data-related costs can easily become scattered across operational budgets rather than appearing as a distinct cost of the amendment itself.
This makes it difficult for clinical operations leaders to answer a basic question:
How much did the amendment actually cost us from a data-management perspective?
Without a consolidated view, the answer remains unclear.
Why This Matters More as Trials Become More Complex
The economics become more significant when every day of a Phase III trial carries a substantial cost.
A week of delay can represent a meaningful financial impact. At the same time, clinical trials are becoming more complex, with decentralised designs and additional data streams increasing the volume and variety of information that sponsors need to manage.
Regulatory expectations are also moving toward stronger risk-based quality management and formal data governance.
That creates a mismatch.
Sponsors need stronger control over clinical data, but many workflows still depend heavily on manual reconciliation, repeated verification, and disconnected systems.
The question, therefore, is not simply whether clinical data management is expensive.
It is whether the current cost structure is still justified.
A Better Way to Calculate the Cost of Clinical Data
A useful starting point is a Total Data Cost framework.
Instead of looking only at direct data-management expenditure, sponsors can bring together five previously separated cost streams:
Direct data management — EDC, database build, cleaning, coding, and database lock.
Monitoring-driven SDV — the cost of verifying source data and associated monitoring activity.
Query resolution — the time required from CRAs, sites, and data-management teams to identify and resolve queries.
Cross-system reconciliation — manual work required to match information across different clinical systems.
Amendment-driven rework — additional configuration, validation, cleaning, and reconciliation caused by protocol changes.
Once these costs are viewed together, the optimisation opportunities become easier to identify.
This is where analytics can be useful. Instead of simply reporting how many queries were generated or how long database lock took, sponsors can examine the cost behind those activities.
For example:
How many hours are spent reconciling data every week?
Which systems generate the most reconciliation work?
How much monitoring activity is spent verifying data that is already accurate?
Which protocol changes generate the greatest amount of downstream rework?
Where are manual handoffs creating avoidable delays?
These questions shift the conversation from "How much did data management cost?" to "Why did it cost this much?"
Where Optimisation Can Start
The source identifies several areas where sponsors can begin reducing unnecessary effort.
Risk-based monitoring
Rather than applying 100% SDV uniformly, risk-based monitoring focuses verification on critical-to-quality data and processes.
The objective is not simply to reduce monitoring. It is to direct monitoring effort toward the areas where verification has the greatest value.
Connected clinical platforms
Disconnected systems create reconciliation work. A more unified clinical data environment can reduce the need to repeatedly move, compare, and validate information across systems.
The source notes that this is particularly relevant given the more than 12 hours per week that data managers can spend on manual reconciliation, cleaning, and review.
eSource adoption
eSource can reduce manual data-entry and query burdens by enabling information to flow from electronic health records into clinical systems.
Implementations involving institutions such as Memorial Sloan Kettering demonstrate how direct electronic capture can become part of a broader strategy for reducing unnecessary data-handling work.
Better protocol design
Protocol complexity has downstream consequences.
Investing more effort in protocol design and using AI-assisted feasibility simulation can help identify potential issues before a trial begins. Reducing unnecessary amendments can, in turn, reduce the data reconfiguration and reconciliation work that follows them.
What Novartis Shows About the Opportunity
The Novartis example in the source illustrates what can happen when clinical data infrastructure is treated as a strategic capability rather than background infrastructure.
Novartis partnered with AWS and Accenture to modernise its drug-development data infrastructure through a GxP-compliant data platform designed to consolidate fragmented clinical data domains.
The initiative targeted a reduction of at least six months per clinical trial development cycle.
Early results cited in the source included 72% faster query speeds, a 60% reduction in storage costs, and more than 160 hours of manual work eliminated in the patient-safety domain. A protocol-generation use case achieved 83% to 87% acceleration in producing compliant protocols.
The broader lesson is not that every sponsor needs to replicate the same technology stack.
It is that individual data improvements can produce value on their own, while a connected data architecture can allow those gains to compound across the development lifecycle.
From Data Management Cost to Data Cost Intelligence
The biggest shift is conceptual.
Clinical data management is often treated as a necessary operational expense. Once the costs of monitoring, reconciliation, query resolution, and amendment-driven rework are brought into the same view, it becomes easier to see where the money is actually going.
That creates a different type of management question.
Instead of asking whether the data-management budget is within its approved range, sponsors can ask:
Which activities are creating the largest data-handling costs, and which of them can be changed?
That distinction matters.
Technology alone will not solve every data-management problem. Nor does reducing a cost automatically improve a trial. Data quality, patient safety, regulatory requirements, and submission integrity still have to remain central.
But without a consolidated cost baseline, sponsors cannot easily distinguish necessary data-management work from avoidable operational friction.
Building the Business Case for Data Optimisation
A practical first step is to conduct a Total Data Cost audit.
The audit should bring direct data-management spending together with monitoring, query resolution, reconciliation, and amendment-related rework.
From there, sponsors can establish a baseline and identify where the largest concentrations of effort sit.
The analysis can then support targeted changes rather than broad technology programmes.
For example, if reconciliation represents a significant share of data-manager time, the business case may focus on system integration. If monitoring consumes substantial resources without materially improving critical data quality, risk-based monitoring may deserve closer examination.
Analytics can also make these patterns easier to communicate to leadership. Power BI consultants can help structure operational data into dashboards that expose workload, reconciliation effort, query trends, monitoring activity, and other cost drivers in a more accessible format.
The goal is not another dashboard for its own sake.
It is a clearer financial and operational picture of clinical data.
The Real Baseline Is Larger Than the Budget Line
The commonly cited 15% allocation for direct data management is useful as a starting point. But it should not be mistaken for the total cost of managing clinical trial data.
Monitoring, SDV, query resolution, reconciliation, and protocol-amendment rework can all contribute to the final burden.
That is why the most useful baseline is not a single percentage. It is a consolidated view of where data-related time and money are actually being spent.
Once that baseline exists, sponsors have something they can optimise.
The next step may involve risk-based monitoring, system integration, eSource, improved protocol design, automation, or a combination of these approaches. The appropriate answer depends on where the largest costs are found.
For organisations considering Power BI implementation, the value should similarly be tied to the underlying operational question: what data needs to be connected, which decisions need to improve, and where can better visibility reduce manual effort or delay?
The broader opportunity is straightforward.
Clinical trial data management does not have to remain a fixed overhead that sits quietly inside multiple budgets. When sponsors measure the full cost of handling clinical data, they can begin treating it as an operational variable — one that can be measured, analysed, and improved.
Perceptive Analytics works with life sciences organisations on AI-enabled automation, advanced analytics, and scalable data engineering. For organisations looking to identify hidden data-management costs, reduce reconciliation and monitoring effort, or build a more connected clinical data environment, a structured data and analytics assessment can help identify where the largest opportunities sit.